摘要

Pancreatic cancer remains the fourth leading cause of cancer-related death in the USA with a 5-year survival rate of 5 %. The effects of epidermal growth factor receptor and vascular endothelial growth factor A blockade with chemotherapy on pancreatic tumor growth were examined. Mice bearing human PANC-1 cell xenografts were divided into three groups: T-CR (gemcitabine, cisplatin, and 5-fluorouracil), T-TR (cetuximab, bevacizumab, gemcitabine, cisplatin, and 5-fluorouracil), and vehicle control (T). The therapies were administered via intraperitoneal injections every 4 days for seven cycles from 7 weeks after cancer cell implantation. Mice treated with T-TR had significant reductions in tumor weight as compared to the control group (p <0.05). Although mice in the T-CR group experienced a significant reduction in body weight gain, serum albumin, and gastrocnemius muscle mass (p <0.05), no such reductions were observed in the T-TR group. Mice treated with T-TR had slightly increased CD11c+ DC and CD49b+ NK cell levels in the spleen (p <0.05) and significantly lower tumor VEGF expression (p <0.05). Tumor carcinoembryonic antigen expression was significantly reduced in both treatment groups (p <0.05). Thus, addition of bevacizumab and cetuximab to gemcitabine, cisplatin, and fluorouracil may represent an effective treatment option for pancreatic cancer that warrants further study.
原文英語
頁(從 - 到)141-150
頁數10
期刊Clinical and Experimental Medicine
17
發行號2
DOIs
出版狀態已發佈 - 五月 1 2017

指紋

gemcitabine
Chemotherapy
Tumor Burden
Pancreatic Neoplasms
Heterografts
Tumors
Fluorouracil
Cisplatin
Drug Therapy
Vascular Endothelial Growth Factor A
Neoplasms
Bearings (structural)
Carcinoembryonic Antigen
Neoplasm Antigens
Intraperitoneal Injections
Epidermal Growth Factor Receptor
Serum Albumin
Natural Killer Cells
Weight Gain
Muscle

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

引用此文

@article{2a91726aa56c4aa290cb46f49979d34f,
title = "Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts",
abstract = "Pancreatic cancer remains the fourth leading cause of cancer-related death in the USA with a 5-year survival rate of 5 {\%}. The effects of epidermal growth factor receptor and vascular endothelial growth factor A blockade with chemotherapy on pancreatic tumor growth were examined. Mice bearing human PANC-1 cell xenografts were divided into three groups: T-CR (gemcitabine, cisplatin, and 5-fluorouracil), T-TR (cetuximab, bevacizumab, gemcitabine, cisplatin, and 5-fluorouracil), and vehicle control (T). The therapies were administered via intraperitoneal injections every 4 days for seven cycles from 7 weeks after cancer cell implantation. Mice treated with T-TR had significant reductions in tumor weight as compared to the control group (p <0.05). Although mice in the T-CR group experienced a significant reduction in body weight gain, serum albumin, and gastrocnemius muscle mass (p <0.05), no such reductions were observed in the T-TR group. Mice treated with T-TR had slightly increased CD11c+ DC and CD49b+ NK cell levels in the spleen (p <0.05) and significantly lower tumor VEGF expression (p <0.05). Tumor carcinoembryonic antigen expression was significantly reduced in both treatment groups (p <0.05). Thus, addition of bevacizumab and cetuximab to gemcitabine, cisplatin, and fluorouracil may represent an effective treatment option for pancreatic cancer that warrants further study.",
keywords = "5-Fluorouracil, Bevacizumab, Cetuximab, Cisplatin, Gemcitabine, Pancreatic cancer, Xenograft",
author = "Tai, {Cheng Jeng} and Hang Wang and Wang, {Chien Kai} and Tai, {Chen Jei} and Huang, {Ming Te} and Wu, {Chih Hsiung} and Chen, {Ray Jade} and Kuo, {Li Jen} and Wei, {Po Lei} and Chang, {Yu Jia} and Chang, {Chun Chao} and Chiou, {Hung Yi} and Wu, {Chang Jer}",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10238-016-0409-2",
language = "English",
volume = "17",
pages = "141--150",
journal = "Zeitschrift fü Die Gesamte Experimentelle Medizin",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",
number = "2",

}

TY - JOUR

T1 - Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts

AU - Tai, Cheng Jeng

AU - Wang, Hang

AU - Wang, Chien Kai

AU - Tai, Chen Jei

AU - Huang, Ming Te

AU - Wu, Chih Hsiung

AU - Chen, Ray Jade

AU - Kuo, Li Jen

AU - Wei, Po Lei

AU - Chang, Yu Jia

AU - Chang, Chun Chao

AU - Chiou, Hung Yi

AU - Wu, Chang Jer

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Pancreatic cancer remains the fourth leading cause of cancer-related death in the USA with a 5-year survival rate of 5 %. The effects of epidermal growth factor receptor and vascular endothelial growth factor A blockade with chemotherapy on pancreatic tumor growth were examined. Mice bearing human PANC-1 cell xenografts were divided into three groups: T-CR (gemcitabine, cisplatin, and 5-fluorouracil), T-TR (cetuximab, bevacizumab, gemcitabine, cisplatin, and 5-fluorouracil), and vehicle control (T). The therapies were administered via intraperitoneal injections every 4 days for seven cycles from 7 weeks after cancer cell implantation. Mice treated with T-TR had significant reductions in tumor weight as compared to the control group (p <0.05). Although mice in the T-CR group experienced a significant reduction in body weight gain, serum albumin, and gastrocnemius muscle mass (p <0.05), no such reductions were observed in the T-TR group. Mice treated with T-TR had slightly increased CD11c+ DC and CD49b+ NK cell levels in the spleen (p <0.05) and significantly lower tumor VEGF expression (p <0.05). Tumor carcinoembryonic antigen expression was significantly reduced in both treatment groups (p <0.05). Thus, addition of bevacizumab and cetuximab to gemcitabine, cisplatin, and fluorouracil may represent an effective treatment option for pancreatic cancer that warrants further study.

AB - Pancreatic cancer remains the fourth leading cause of cancer-related death in the USA with a 5-year survival rate of 5 %. The effects of epidermal growth factor receptor and vascular endothelial growth factor A blockade with chemotherapy on pancreatic tumor growth were examined. Mice bearing human PANC-1 cell xenografts were divided into three groups: T-CR (gemcitabine, cisplatin, and 5-fluorouracil), T-TR (cetuximab, bevacizumab, gemcitabine, cisplatin, and 5-fluorouracil), and vehicle control (T). The therapies were administered via intraperitoneal injections every 4 days for seven cycles from 7 weeks after cancer cell implantation. Mice treated with T-TR had significant reductions in tumor weight as compared to the control group (p <0.05). Although mice in the T-CR group experienced a significant reduction in body weight gain, serum albumin, and gastrocnemius muscle mass (p <0.05), no such reductions were observed in the T-TR group. Mice treated with T-TR had slightly increased CD11c+ DC and CD49b+ NK cell levels in the spleen (p <0.05) and significantly lower tumor VEGF expression (p <0.05). Tumor carcinoembryonic antigen expression was significantly reduced in both treatment groups (p <0.05). Thus, addition of bevacizumab and cetuximab to gemcitabine, cisplatin, and fluorouracil may represent an effective treatment option for pancreatic cancer that warrants further study.

KW - 5-Fluorouracil

KW - Bevacizumab

KW - Cetuximab

KW - Cisplatin

KW - Gemcitabine

KW - Pancreatic cancer

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=84961202641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961202641&partnerID=8YFLogxK

U2 - 10.1007/s10238-016-0409-2

DO - 10.1007/s10238-016-0409-2

M3 - Article

VL - 17

SP - 141

EP - 150

JO - Zeitschrift fü Die Gesamte Experimentelle Medizin

JF - Zeitschrift fü Die Gesamte Experimentelle Medizin

SN - 1591-8890

IS - 2

ER -